Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to $4.0 million.

  • Profound Medical's Accumulated Expenses rose 5259.32% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 5259.32%. This contributed to the annual value of $2.8 million for FY2024, which is 1719.72% up from last year.
  • As of Q3 2025, Profound Medical's Accumulated Expenses stood at $4.0 million, which was up 5259.32% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, Profound Medical's Accumulated Expenses peaked at $4.0 million during Q3 2025, and registered a low of $2.1 million during Q2 2024.
  • Over the past 3 years, Profound Medical's median Accumulated Expenses value was $2.7 million (recorded in 2024), while the average stood at $2.9 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 1719.72% in 2024, then surged by 8384.91% in 2025.
  • Profound Medical's Accumulated Expenses (Quarter) stood at $2.4 million in 2023, then grew by 17.2% to $2.8 million in 2024, then surged by 40.11% to $4.0 million in 2025.
  • Its Accumulated Expenses was $4.0 million in Q3 2025, compared to $3.8 million in Q2 2025 and $3.4 million in Q1 2025.